How much does ensidipine cost at Bigbear Pharmaceuticals?

Enasidenib is an oral, targeted inhibitor used to treat a rare myeloblastic tumor called refractory or relapsed acute myeloid leukemia (AML). Its mechanism of action is to inhibit the activity of IDH2 (isocitrate dehydrogenase 2) mutant, thereby blocking abnormal metabolic pathways and promoting the differentiation of leukemia cells into normal hematopoietic cells.

bigbearPharmaceutical is Laos Bigbear Pharmaceutical. Currently, there is no ensidipine from Bigbear Pharmaceutical, only the Lao Lucius version of ensidipine.

Ensidipine has not yet obtained marketing approval in China, which means that domestic patients cannot directly purchase the drug and must resort to overseas purchase channels. In foreign countries, relatively affordable drugs are generic drugs, especially those produced in Laos and Bangladesh, which sell for between 2,000 and 4,000 yuan. It is worth mentioning that these generic drugs are very close to the original drugs in terms of pharmaceutical ingredients.

Refractory or relapsedAML is a type of leukemia that is difficult to treat and has a low response rate to traditional chemotherapy and bone marrow transplantation. In this setting, ensidipine as a novel treatment option offers patients a new opportunity to potentially improve prognosis.

Ensidipine is usually taken by mouth once daily. Patients receiving ensidipine need to be closely monitored for treatment response and adverse reactions to ensure the safety and effectiveness of the treatment. Possible adverse reactions include but are not limited to abnormal liver function, nausea, vomiting, fatigue, etc. Therefore, doctors typically perform regular liver function tests and other clinical monitoring during treatment.

Clinical trial data of ensidipine show that in some patients, it can significantly prolong progression-free survival and bring about a certain degree of remission. However, the effects of treatment may vary between patients, so the decision to use ensidipine needs to be based on the patient's individual situation and treatment plan.